Patents by Inventor Johan Neyts

Johan Neyts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12286423
    Abstract: The invention provides compounds of Formula (I): as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: April 29, 2025
    Assignees: Novartis AG, Katholieke Universiteit Leuven, Korea Research Institute of Chemical Technology
    Inventors: Johan Neyts, Daniel Poon, Keith Bruce Pfister, Young-Sik Jung, Soo Bong Han, Yashwardhan R. Malpani, Prashant Chakrasali, Bishyajit Kumar Biswas, Chong-Kyo Lee, Chonsaeng Kim, Jin Soo Shin, Hae Soo Kim
  • Publication number: 20250099568
    Abstract: The invention describes chimeric Flavivirus constructs comprising lyssavirus G proteins in the E/NS1 intergenic region. FIG. 1A.
    Type: Application
    Filed: July 19, 2024
    Publication date: March 27, 2025
    Applicant: KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Kai Dallmeier, Niraj Mishra, Johan Neyts, Lorena Senchez
  • Patent number: 12083092
    Abstract: This disclosure provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: September 10, 2024
    Assignees: Novartis AG, Katholieke Universiteit Leuven, Korea Research Institute of Chemical Technology
    Inventors: Johan Neyts, Daniel Poon, Keith Bruce Pfister, Young-Sik Jung, Soo Bong Han, Yashwardhan R. Malpani, Prashant Chakrasali, Sang-Ho Lee, Chong-Kyo Lee, Chonsaeng Kim, Jin Soo Shin, Hae Soo Kim
  • Patent number: 12070494
    Abstract: The invention describes chimeric Flavivirus constructs comprising lyssavirus G proteins in the E/NS1 intergenic region.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: August 27, 2024
    Assignee: KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Kai Dallmeier, Niraj Mishra, Johan Neyts, Lorena Sanchez
  • Patent number: 12012411
    Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: June 18, 2024
    Assignee: Katholieke Universiteit Leuven
    Inventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Michael McNaughton, Arnaud Marchand, Johan Neyts, Wim Smets, Mohamed Koukni
  • Patent number: 11904024
    Abstract: The present invention relates to an eye-drop composition comprising 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one, and the use thereof for the diagnosis and treatment of herpetic eye infections in companion animals.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: February 20, 2024
    Assignee: Aratana Therapeutics, Inc.
    Inventors: Nesya Goris, Johan Neyts, Erwin Blomsma, Stefaan Wera, Ainola Billiet, Joeri Auwerx, Veerle Debeurme, Maryline Roe, Pascal Puig
  • Publication number: 20230406889
    Abstract: The invention relates to polynucleotides comprising the sequence of a flavivirus preceded by a sequence encoding an N terminal part of a flavivirus Capsid protein, an immunogenic protein, or a part thereof comprising a an immunogenic peptide, and a 2A cleaving peptide, and to the virus encoded by such sequences. The invention further relates to the use of such polynucleotides and viruses as vaccines.
    Type: Application
    Filed: May 5, 2023
    Publication date: December 21, 2023
    Applicant: Katholieke Universiteit Leuven
    Inventors: Robbert Boudewijns, Kai Dallmeier, Johan Neyts
  • Patent number: 11680084
    Abstract: The invention relates to polynucleotides comprising the sequence of a flavivirus preceded by a sequence encoding an N terminal part of a flavivirus Capsid protein, an immunogenic protein, or a part thereof comprising a an immunogenic peptide, and a 2A cleaving peptide, and to the virus encoded by such sequences. The invention further relates to the use of such polynucleotides and viruses as vaccines.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: June 20, 2023
    Assignee: KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Robbert Boudewijns, Kai Dallmeier, Johan Neyts
  • Patent number: 11566025
    Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: January 31, 2023
    Assignee: Katholieke Universiteit Leuven
    Inventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Mohamed Koukni, Arnaud Marchand, Johan Neyts, Wim Smets
  • Patent number: 11351240
    Abstract: The present invention relates to chimeric yellow fever—Zika strains and attenuated versions thereof, wherein the nucleotide sequence encoding the signal sequence and prME protein of said yellow virus is replaced by a nucleotide sequence encoding the signal sequence and the prME protein of a Zika virus.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: June 7, 2022
    Assignee: Katholieke Universiteit Leuven
    Inventors: Kai Dallmeier, Dieudonné Buh Kum, Niraj Mishra, Johan Neyts, Michael Alexander Schmid
  • Publication number: 20220168412
    Abstract: A polynucleotide comprising the sequence of a live, infectious, attenuated Zika-Japanese encephalitis (JEV) chimeric virus wherein the nucleotide sequence encoding the prME protein of said Zika virus is replaced by a nucleotide sequence encoding the prME protein of a Japanese encephalitis virus, so that said prME protein of said Japanese encephalitis virus is expressed.
    Type: Application
    Filed: April 10, 2020
    Publication date: June 2, 2022
    Inventors: Kai Dallmeier, Dieudonné Buh Kum, Niraj Mishra, Johan Neyts
  • Publication number: 20220106321
    Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Application
    Filed: November 30, 2021
    Publication date: April 7, 2022
    Applicant: Katholieke Universiteit Leuven
    Inventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Michael McNaughton, Arnaud Marchand, Johan Neyts, Wim Smets, Mohamed Koukni
  • Patent number: 11279704
    Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: March 22, 2022
    Assignee: Katholieke Universiteit Leuven
    Inventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Michael McNaughton, Arnaud Marchand, Johan Neyts, Wim Smets, Mohamed Koukni
  • Publication number: 20210353735
    Abstract: The invention describes chimeric Flavivirus constructs comprising lyssavirus G proteins in the E/NS1 intergenic region.
    Type: Application
    Filed: September 6, 2019
    Publication date: November 18, 2021
    Inventors: Kai Dallmeier, Niraj Mishra, Johan Neyts, Lorena Sanchez
  • Patent number: 10967074
    Abstract: The present invention relates to an eye-drop composition comprising 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one, and the use thereof for the diagnosis and treatment of herpetic eye infections in companion animals.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: April 6, 2021
    Assignee: ARATANA THERAPEUTICS, INC.
    Inventors: Nesya Goris, Johan Neyts, Erwin Blomsma, Stefaan Wera, Ainola Billiet, Joeri Auwerx, Veerle Debeurme, Maryline Roe, Pascal Puig
  • Publication number: 20200331969
    Abstract: The invention relates to polynucleotides comprising the sequence of a flavivirus preceded by a sequence encoding an N terminal part of a flavivirus Capsid protein, an immunogenic protein, or a part thereof comprising a an immunogenic peptide, and a 2A cleaving peptide, and to the virus encoded by such sequences. The invention further relates to the use of such polynucleotides and viruses as vaccines.
    Type: Application
    Filed: October 5, 2018
    Publication date: October 22, 2020
    Inventors: Robbert Boudewijns, Kai Dallmeier, Johan Neyts
  • Publication number: 20200316187
    Abstract: The present invention relates to chimeric yellow fever—Zika strains and attenuated versions thereof, wherein the nucleotide sequence encoding the signal sequence and prME protein of said yellow virus is replaced by a nucleotide sequence encoding the signal sequence and the prME protein of a Zika virus.
    Type: Application
    Filed: October 5, 2018
    Publication date: October 8, 2020
    Inventors: Kai Dallmeier, Dieudonné Buh Kum, Niraj Mishra, Johan Neyts, Michael Alexander Schmid
  • Publication number: 20200223845
    Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Application
    Filed: February 24, 2020
    Publication date: July 16, 2020
    Applicant: Katholieke Universiteit Leuven
    Inventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Mohamed Koukni, Arnaud Marchand, Johan Neyts, Wim Smets
  • Patent number: 10633378
    Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: April 28, 2020
    Assignee: Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Mohamed Koukni, Arnaud Marchand, Johan Neyts, Wim Smets
  • Patent number: 10550123
    Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: February 4, 2020
    Assignee: Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Michael McNaughton, Arnaud Marchand, Johan Neyts, Wim Smets, Mohamed Koukni